BioSpace News Archive

The Company will be holding Q&As at the end of the webinar. All questions will be preapproved at managements discretion and subject to time constraints.

Andreia joins from TFS Health Science, a global CRO, where she was the EVP HR, Talent Acquisition and Marketing & Communications.

SurGenTec®, a privately held spine and orthopedic technology company based in Boca Raton, FL, announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for ION™ Screw, its proprietary stand-alone spine fixation implant.

Athira Pharma, Inc. (NASDAQ: ATHA), today announced preclinical data for the active metabolite of fosgonimeton, a novel small molecule candidate for Alzheimer’s, Parkinson’s disease dementia and Dementia with Lewy bodies, and ATH-1020, an orally available, brain-penetrant small molecule candidate for neuropsychiatric conditions.

Bristol-Myers Squibb Company, with its wholly-owned subsidiary Celgene Corporation, announced the accepted amounts and pricing terms of their previously announced 22 separate offers to purchase for cash notes issued by the Offerors listed in the tables listed herein.

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the company’s fourth quarter and full year 2021 financial results on Thursday, March 10, 2022 after the close of U.S. financial markets.

AVITA Medical, Inc., a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced that they have been awarded a group purchasing agreement with Premier, Inc.

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the fourth quarter and full year ended December 31, 2021.

Ascendis Pharma A/S announced financial results for the full year ended December 31, 2021 and provided a business update.

Hepatitis A is a liver disease caused by hepatitis A virus that can lead to mild to severe illness.